To investigate whether CD8+ T cells identified in our study can predict tumour immune evasion and immune therapy resistance in NSCLC, we evaluated the expression of their main marker genes of CD8+ cytolytic T lymphocytes (CTLs) in the patients who received anti‐CTLA4 or anti‐PD1 therapy in scTIME Portal.49 This evidence concerns the gene PDCD1 and neoplasm.